Literature DB >> 28700848

The Economics of Indication-Based Drug Pricing.

Amitabh Chandra1, Craig Garthwaite1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28700848     DOI： 10.1056/NEJMp1705035

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

2.  Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Authors:  Jorge Mestre-Ferrandiz; Néboa Zozaya; Bleric Alcalá; Álvaro Hidalgo-Vega
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

3.  Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Authors:  Scott K Sherman; Joel J Lange; Fadi S Dahdaleh; Rahul Rajeev; T Clark Gamblin; Blase N Polite; Kiran K Turaga
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

4.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

5.  The economics of alternative payment models for pharmaceuticals.

Authors:  Jakub P Hlávka; Jeffrey C Yu; Dana P Goldman; Darius N Lakdawalla
Journal:  Eur J Health Econ       Date:  2021-03-16

Review 6.  The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.

Authors:  Matthew H Forsberg; Amritava Das; Krishanu Saha; Christian M Capitini
Journal:  Ther Clin Risk Manag       Date:  2018-09-03       Impact factor: 2.423

7.  Precision medicine and monoclonal antibodies: breach of promise?

Authors:  Livio Garattini; Anna Padula
Journal:  Croat Med J       Date:  2019-06-13       Impact factor: 1.351

8.  Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.

Authors:  Hideki Maeda; Ayano Okabe; Kenichi Sakakura; Daniel Bin Ng; Manabu Akazawa
Journal:  BMC Health Serv Res       Date:  2021-12-11       Impact factor: 2.655

9.  Leveraging the Learning Health Care Model to Improve Equity in the Age of Genomic Medicine.

Authors:  Katherine D Blizinsky; Vence L Bonham
Journal:  Learn Health Syst       Date:  2017-11-27

10.  Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.

Authors:  Francesco Trotta; Flavia Mayer; Francesco Barone-Adesi; Immacolata Esposito; Ranadhir Punreddy; Roberto Da Cas; Giuseppe Traversa; Francesco Perrone; Nello Martini; Bishal Gyawali; Antonio Addis
Journal:  BMJ Open       Date:  2019-12-10       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.